Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)

Group 1 - Vaxcyte, Inc. (NASDAQ:PCVX) is recognized as a high-potential biotech stock, with a Buy rating maintained by Bank of America Securities and a price target set at $134.00 [1] - On September 30, Vaxcyte announced a new agreement with Thermo Fisher Scientific Inc. to enhance commercial manufacturing for its broad-spectrum pneumococcal conjugate vaccines in the United States [2] - The agreement with Thermo Fisher includes custom commercial fill-finish capacity at its Greenville, North Carolina facility, representing a long-term commitment valued at up to $1 billion [3] Group 2 - Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines, including broad-spectrum conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases [4]